Abstract 71P
Background
Despite durable responses achieved with Immune Checkpoint Inhibitors (ICIs), data about optimal duration of treatment, especially in the context of adverse events, remain scarce.
Methods
A systematic literature search was conducted in three electronic databases until July 2024. Studies referring to melanoma patients who ceased ICIs electively (i.e. due to complete response (CR), protocol completion or patient/physician’s wish) or due to treatment-limiting toxicities (TLTs) were selected. Relapse rates (RRs) post cessation, time to PD, rechallenge and disease control rate (DCR) after 2nd course were the main outcomes. Random-effects models were preferred, and subgroup and sensitivity analyses were conducted to investigate possible sources of heterogeneity.
Results
38 and 35 studies were included in qualitative and quantitative synthesis, respectively. From 2542 patients who discontinued treatment with ICIs, 495 experienced progression (n=34, RR 20.9%,95%CI 17.1–24.7%, I285%); higher rates were detected in patients with TLTs compared to elective disc. Mean time to PD was 14.26 months (n=18, mean time 14.26,95%CI 11.54–16.98,I293%) and was numerically longer in patients ceased for CR compared to patients with TLTs. Treatment duration before cessation was not associated with risk and time to relapse, while mucosal melanomas and non-CR as BOR during treatment led to increased risk for relapse and shorter time to PD compared to other histologic subtypes or CR. Rechallenge with ICI resulted in 57.3% DCR and 28.6% pooled CR rates (n=22, CR rate 28.6%, 95%CI 17.1–40.2, I268%). Subgroup analysis (type of ICI) and sensitivity analyses did not alter the results significantly. Table: 71P
n | Relapse Rate (%,95%CI) | n | Time to PD (mean,95% CI) | n | DCR rate (%,95%CI) | |
Overall population | 34 | 20.9 (17.1 – 24.7) | 18 | 14.2 (11.54 – 16.98) | 22 | 57.3 (43.9 – 70.6) |
Elective disc. | 27 | 15.9 (12.4 – 19.4) | 15 | 14.7 (11.77 – 17.82) | - | |
CR | 22 | 13.2 (10.5 – 16.0) | 14 | 15.8 (12.29 – 19.47) | - | |
TLTs | 14 | 25.9 (18.3 – 33.4) | 5 | 13.1 (9.69 – 16.54) | - |
Conclusions
Discontinuation of ICIs in patients without progression is possible. Outcomes to rechallenge with ICIs may differ depending on the reason for discontinuation, but remains a considerable option.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
U. Leiter-Stoppke: Financial Interests, Personal, Advisory Board, and speaker's honoraria: Sun Pharma, Regeneron, Sanofi; Financial Interests, Personal, Advisory Board: Pierre Fabre, Novartis, Almirall Hermal; Financial Interests, Institutional, Research Grant: MSD. L. Flatz: Financial Interests, Personal, Full or part-time Employment, Section Head of Dermato-oncology: University Hospital of Tübingen; Financial Interests, Personal, Stocks/Shares, Founder: Hookipa Pharma, Humion AG; Financial Interests, Personal, Ownership Interest, Founder: Abtherix GmbH, Schmelzberg GmbH; Financial Interests, Personal, Royalties, IP owner together with University of Zurich: Hookipa Pharma; Non-Financial Interests, Personal, Advisory Role: Philogen. T.M.S. Amaral: Financial Interests, Personal, Writing Engagement: CeCaVa, Medtrix; Financial Interests, Personal, Invited Speaker: BMS, Novartis, Pierre Fabre, Neracare; Financial Interests, Personal, Advisory Board: Delcath, Philogen; Financial Interests, Institutional, Funding: Novartis, Neracare, Sanofi, Skyline-Dx, Pascoe, MNI - Naturwissenschaftliches und Medizinisches Institut; Financial Interests, Institutional, Research Grant: Novartis, iFIT; Financial Interests, Institutional, Local PI: IO Biotech, MSD, University Hospital, Essen, Roche, BMS, BioNTech, Philogen, Pfizer, Immunocore, HUYA Bioscience, AstraZeneca, Agenus Inc., Regeneron; Financial Interests, Institutional, Coordinating PI: Unicancer; Non-Financial Interests, Personal, Member: Portuguese Society for Medical Oncology, ASCO; Other, Personal, Other, Clinical expert in the area of medical oncology: INFARMED - PT. All other authors have declared no conflicts of interest.
Resources from the same session
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
Resources:
Abstract
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
Resources:
Abstract
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
Resources:
Abstract
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
Resources:
Abstract
114P - Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS=5: Updated results from a real-world study
Presenter: Qi Xu
Session: Poster Display session
Resources:
Abstract
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
Resources:
Abstract
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
Resources:
Abstract
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
Resources:
Abstract
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session
Resources:
Abstract
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
Resources:
Abstract